Compare ProShares UltraShort Bloomberg Natural Gas ETF (KOLD) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ProShares UltraShort Bloomberg Natural Gas ETF vs BIO-TECHNE Corp — how do they compare? ProShares UltraShort Bloomberg Natural Gas ETF trades at $24.75 (market cap $141.25M), while BIO-TECHNE Corp trades at $72.46 (market cap $11.36B). The key difference: BIO-TECHNE Corp is far larger — about 80.4× ProShares UltraShort Bloomberg Natural Gas ETF's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while ProShares UltraShort Bloomberg Natural Gas ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold ProShares UltraShort Bloomberg Natural Gas ETF for 10 Days and BIO-TECHNE Corp for 64 Days on average.
| KOLD | TECH | |
|---|---|---|
Market Cap | $141.25M | $11.36B |
Volume | 5,492,367 | 5,390,331 |
Sector | Leveraged / Inverse | Health |
52-Week High | $49.39 | $72.61 |
52-Week Low | $13.58 | $43.31 |
Typical Hold Time | 10 Days | 64 Days |
Enterprise Value | — | $11.39B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KOLD is trading at $25.68, up 3.38% today, but faces bearish technical signals with 15 sell indicators versus 2 buy signals. The stock is trading near its pivot point of $25 with immediate resistance at $26 and support at $25. Recent news highlights volatility in natural gas markets with record production levels and geopolitical tensions affecting energy sector sentiment.
The outlook remains cautious with strong bearish momentum indicators and fundamental data gaps. Investment opportunity exists for contrarian traders near support levels, but risks include energy price volatility and production oversupply concerns. Technical weakness suggests potential for further downside testing of $24-$25 support zone.
TECH trades at $72.45, near its 52-week high of $72.70 (Defense World, 2026-09-28), with a slight 0.11% decline over 24 hours. The stock shows a bullish technical signal, supported by moving averages, while fundamentals reveal a high P/E of 62.46 and net income margin of 14.97% for 2025. Recent news highlights shareholder approval of its acquisition by Merck KGaA at $73.00 per share (PRNewsWire, 2026-09-23), a key catalyst for near-term price action.
The outlook is mixed: the acquisition offers upside to the current price, but elevated valuation ratios pose risks if earnings growth falters. Analyst consensus is divided with 46% buy ratings, and net income volatility from 2022-2025 signals execution challenges. Investors should weigh the acquisition premium against fundamental sustainability in a competitive life sciences tools sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ProShares UltraShort Bloomberg Natural Gas ETF
KOLD is an inverse leveraged ETF that seeks to provide two times (2x) the inverse daily performance of the Bloomberg Natural Gas Subindex. It is designed for investors looking to profit from falling natural gas prices.
Read more on KOLD →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
